http:\/\/www.lsoncology.com\/press_releases\/release\/pr_1250033310<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Not a full case report or a medical first but it is the first patient in a phase 1 trial of this intriguing, light-activated chemotherapy drug in children with plexiform neurofibromas. “Light Sciences Oncology, Inc. (LSO) today announced the treatment of the first patient in an investigator-sponsored Phase 1 pediatric study of its novel light-activated […]<\/p>\n
Read More…<\/a><\/p>\n","protected":false},"author":65,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[711],"tags":[],"class_list":["post-46","post","type-post","status-publish","format-standard","hentry","category-cases-in-the-news"],"yoast_head":"\nPhase 1 trial of Talaporfin (Laserphyrin \/ NPe6) in neurofibromatosis treats first patient - BMJ Case Reports blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/blogs.bmj.com\/case-reports\/2009\/08\/15\/phase-1-trial-of-talaporfin-laserphyrin-npe6-in-neurofibromatosis-treats-first-patient\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Phase 1 trial of Talaporfin (Laserphyrin \/ NPe6) in neurofibromatosis treats first patient - BMJ Case Reports blog\" \/>\n<meta property=\"og:description\" content=\"Not a full case report or a medical first but it is the first patient in a phase 1 trial of this intriguing, light-activated chemotherapy drug in children with plexiform neurofibromas. “Light Sciences Oncology, Inc. (LSO) today announced the treatment of the first patient in an investigator-sponsored Phase 1 pediatric study of its novel light-activated [...]Read More...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/blogs.bmj.com\/case-reports\/2009\/08\/15\/phase-1-trial-of-talaporfin-laserphyrin-npe6-in-neurofibromatosis-treats-first-patient\/\" \/>\n<meta property=\"og:site_name\" content=\"BMJ Case Reports blog\" \/>\n<meta property=\"article:published_time\" content=\"2009-08-15T10:50:51+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/case-reports\\\/2009\\\/08\\\/15\\\/phase-1-trial-of-talaporfin-laserphyrin-npe6-in-neurofibromatosis-treats-first-patient\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/case-reports\\\/2009\\\/08\\\/15\\\/phase-1-trial-of-talaporfin-laserphyrin-npe6-in-neurofibromatosis-treats-first-patient\\\/\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"Phase 1 trial of Talaporfin (Laserphyrin \\\/ NPe6) in neurofibromatosis treats first patient\",\"datePublished\":\"2009-08-15T10:50:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/case-reports\\\/2009\\\/08\\\/15\\\/phase-1-trial-of-talaporfin-laserphyrin-npe6-in-neurofibromatosis-treats-first-patient\\\/\"},\"wordCount\":141,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/case-reports\\\/#organization\"},\"articleSection\":[\"Cases in the news\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/case-reports\\\/2009\\\/08\\\/15\\\/phase-1-trial-of-talaporfin-laserphyrin-npe6-in-neurofibromatosis-treats-first-patient\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/case-reports\\\/2009\\\/08\\\/15\\\/phase-1-trial-of-talaporfin-laserphyrin-npe6-in-neurofibromatosis-treats-first-patient\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/case-reports\\\/2009\\\/08\\\/15\\\/phase-1-trial-of-talaporfin-laserphyrin-npe6-in-neurofibromatosis-treats-first-patient\\\/\",\"name\":\"Phase 1 trial of Talaporfin (Laserphyrin \\\/ NPe6) in neurofibromatosis treats first patient - BMJ Case Reports blog\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/case-reports\\\/#website\"},\"datePublished\":\"2009-08-15T10:50:51+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/case-reports\\\/2009\\\/08\\\/15\\\/phase-1-trial-of-talaporfin-laserphyrin-npe6-in-neurofibromatosis-treats-first-patient\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/case-reports\\\/2009\\\/08\\\/15\\\/phase-1-trial-of-talaporfin-laserphyrin-npe6-in-neurofibromatosis-treats-first-patient\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/case-reports\\\/2009\\\/08\\\/15\\\/phase-1-trial-of-talaporfin-laserphyrin-npe6-in-neurofibromatosis-treats-first-patient\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/blogs.bmj.com\\\/case-reports\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Phase 1 trial of Talaporfin (Laserphyrin \\\/ NPe6) in neurofibromatosis treats first patient\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/case-reports\\\/#website\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/case-reports\\\/\",\"name\":\"BMJ Case Reports blog\",\"description\":\"The official BMJ Case Reports blog, a place to discuss wider medical progress and implications.\",\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/case-reports\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/blogs.bmj.com\\\/case-reports\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/case-reports\\\/#organization\",\"name\":\"BMJ Case Reports blog\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/case-reports\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/case-reports\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/case-reports\\\/files\\\/2017\\\/10\\\/blog-logo-case-reports.png\",\"contentUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/case-reports\\\/files\\\/2017\\\/10\\\/blog-logo-case-reports.png\",\"width\":224,\"height\":34,\"caption\":\"BMJ Case Reports blog\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/case-reports\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/case-reports\\\/author\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Phase 1 trial of Talaporfin (Laserphyrin \/ NPe6) in neurofibromatosis treats first patient - BMJ Case Reports blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/blogs.bmj.com\/case-reports\/2009\/08\/15\/phase-1-trial-of-talaporfin-laserphyrin-npe6-in-neurofibromatosis-treats-first-patient\/","og_locale":"en_US","og_type":"article","og_title":"Phase 1 trial of Talaporfin (Laserphyrin \/ NPe6) in neurofibromatosis treats first patient - BMJ Case Reports blog","og_description":"Not a full case report or a medical first but it is the first patient in a phase 1 trial of this intriguing, light-activated chemotherapy drug in children with plexiform neurofibromas. “Light Sciences Oncology, Inc. (LSO) today announced the treatment of the first patient in an investigator-sponsored Phase 1 pediatric study of its novel light-activated [...]Read More...","og_url":"https:\/\/blogs.bmj.com\/case-reports\/2009\/08\/15\/phase-1-trial-of-talaporfin-laserphyrin-npe6-in-neurofibromatosis-treats-first-patient\/","og_site_name":"BMJ Case Reports blog","article_published_time":"2009-08-15T10:50:51+00:00","twitter_card":"summary_large_image","twitter_misc":{"Written by":"","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/blogs.bmj.com\/case-reports\/2009\/08\/15\/phase-1-trial-of-talaporfin-laserphyrin-npe6-in-neurofibromatosis-treats-first-patient\/#article","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/case-reports\/2009\/08\/15\/phase-1-trial-of-talaporfin-laserphyrin-npe6-in-neurofibromatosis-treats-first-patient\/"},"author":{"name":"","@id":""},"headline":"Phase 1 trial of Talaporfin (Laserphyrin \/ NPe6) in neurofibromatosis treats first patient","datePublished":"2009-08-15T10:50:51+00:00","mainEntityOfPage":{"@id":"https:\/\/blogs.bmj.com\/case-reports\/2009\/08\/15\/phase-1-trial-of-talaporfin-laserphyrin-npe6-in-neurofibromatosis-treats-first-patient\/"},"wordCount":141,"commentCount":0,"publisher":{"@id":"https:\/\/blogs.bmj.com\/case-reports\/#organization"},"articleSection":["Cases in the news"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/blogs.bmj.com\/case-reports\/2009\/08\/15\/phase-1-trial-of-talaporfin-laserphyrin-npe6-in-neurofibromatosis-treats-first-patient\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/blogs.bmj.com\/case-reports\/2009\/08\/15\/phase-1-trial-of-talaporfin-laserphyrin-npe6-in-neurofibromatosis-treats-first-patient\/","url":"https:\/\/blogs.bmj.com\/case-reports\/2009\/08\/15\/phase-1-trial-of-talaporfin-laserphyrin-npe6-in-neurofibromatosis-treats-first-patient\/","name":"Phase 1 trial of Talaporfin (Laserphyrin \/ NPe6) in neurofibromatosis treats first patient - BMJ Case Reports blog","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/case-reports\/#website"},"datePublished":"2009-08-15T10:50:51+00:00","breadcrumb":{"@id":"https:\/\/blogs.bmj.com\/case-reports\/2009\/08\/15\/phase-1-trial-of-talaporfin-laserphyrin-npe6-in-neurofibromatosis-treats-first-patient\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/blogs.bmj.com\/case-reports\/2009\/08\/15\/phase-1-trial-of-talaporfin-laserphyrin-npe6-in-neurofibromatosis-treats-first-patient\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/blogs.bmj.com\/case-reports\/2009\/08\/15\/phase-1-trial-of-talaporfin-laserphyrin-npe6-in-neurofibromatosis-treats-first-patient\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/blogs.bmj.com\/case-reports\/"},{"@type":"ListItem","position":2,"name":"Phase 1 trial of Talaporfin (Laserphyrin \/ NPe6) in neurofibromatosis treats first patient"}]},{"@type":"WebSite","@id":"https:\/\/blogs.bmj.com\/case-reports\/#website","url":"https:\/\/blogs.bmj.com\/case-reports\/","name":"BMJ Case Reports blog","description":"The official BMJ Case Reports blog, a place to discuss wider medical progress and implications.","publisher":{"@id":"https:\/\/blogs.bmj.com\/case-reports\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/blogs.bmj.com\/case-reports\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/blogs.bmj.com\/case-reports\/#organization","name":"BMJ Case Reports blog","url":"https:\/\/blogs.bmj.com\/case-reports\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/blogs.bmj.com\/case-reports\/#\/schema\/logo\/image\/","url":"https:\/\/blogs.bmj.com\/case-reports\/files\/2017\/10\/blog-logo-case-reports.png","contentUrl":"https:\/\/blogs.bmj.com\/case-reports\/files\/2017\/10\/blog-logo-case-reports.png","width":224,"height":34,"caption":"BMJ Case Reports blog"},"image":{"@id":"https:\/\/blogs.bmj.com\/case-reports\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"","url":"https:\/\/blogs.bmj.com\/case-reports\/author\/"}]}},"_links":{"self":[{"href":"https:\/\/blogs.bmj.com\/case-reports\/wp-json\/wp\/v2\/posts\/46","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.bmj.com\/case-reports\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.bmj.com\/case-reports\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/case-reports\/wp-json\/wp\/v2\/users\/65"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/case-reports\/wp-json\/wp\/v2\/comments?post=46"}],"version-history":[{"count":0,"href":"https:\/\/blogs.bmj.com\/case-reports\/wp-json\/wp\/v2\/posts\/46\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.bmj.com\/case-reports\/wp-json\/wp\/v2\/media?parent=46"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.bmj.com\/case-reports\/wp-json\/wp\/v2\/categories?post=46"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.bmj.com\/case-reports\/wp-json\/wp\/v2\/tags?post=46"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}